PDF(Pubmed)
Abstract：
The present letter to the editor is related to the review with the title \"Past, present, and future of long-term treatment for hepatitis B virus.\" Chronic hepatitis B (CHB) represents an important and pressing public health concern. Timely identification and effective antiviral therapy hold the potential to reduce liver-related mortality attributable to chronic infection with hepatitis B virus (HBV) substantially. However, the current global treatment rates for CHB remain conspicuously low, with the excessively stringent treatment criteria advocated by national CHB guidelines being a contributing factor to these low rates. Nevertheless, recent strides in comprehending this malady and the emergence of novel antiviral agents prompt the imperative re-evaluation of treatment standards to extend the sphere of potential beneficiaries. An impending need arises for a novel paradigm for the classification of patients with CHB, the expansion of antiviral treatment eligibility for HBV-infected individuals, and even the streamlining of the diagnostic process for CHB to amplify cost-effectiveness and augment survival prospects.
摘要：
给编辑的这封信与标题为“过去”的评论有关，present,以及乙型肝炎病毒长期治疗的未来。“慢性乙型肝炎（CHB）代表了一个重要而紧迫的公共卫生问题。及时识别和有效的抗病毒治疗有可能降低与乙型肝炎病毒（HBV）慢性感染相关的肝脏死亡率。然而,目前CHB的全球治疗率仍然明显较低，国家CHB指南提倡的过于严格的治疗标准是导致这些低费率的一个因素。然而，最近在理解这种疾病方面取得的进展和新型抗病毒药物的出现促使人们必须重新评估治疗标准，以扩大潜在受益者的范围。一个迫在眉睫的需要出现一个新的范式为CHB患者的分类，HBV感染者抗病毒治疗资格的扩大，甚至简化CHB的诊断过程，以扩大成本效益和增加生存前景。
